<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442935</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 14 / ACCORD 21/0905</org_study_id>
    <nct_id>NCT01442935</nct_id>
  </id_info>
  <brief_title>Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases</brief_title>
  <official_title>Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the
      experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi
      chemotherapy plus targeted therapy); in both arms the targeted therapy is selected according
      to K-Ras status of the patient's tumor.

      The secondary objectives are to evaluate the objective response rate (CR and PR) after 4
      cycles of treatment, according the RECIST V1.1 evaluation scale.

        -  the rate of complete remission (CR) at 6 months after the last study treatment (hepatic
           surgery or last chemotherapy cycle).

        -  the specific rates of resection R0, R1, R2.

        -  the complete pathological response Rate,

        -  the relapse-free survival rate in (R0 or R1) resected patients,

        -  the response duration in non-resected patients,

        -  the toxicity according to CTC AE V4 scale except for the neurotoxicity that will be
           evaluated with the Levi scale,

        -  the post operative complications using the DINDO classification,

        -  the progression-free survival (PFS) and overall survival (OS).

      The objectives of the biological study are:

        -  to evaluate tumor-related predictive factors such as somatic mutations (KRAS, BRAF,
           TP53) and genetic amplification related factors (EGFR),

        -  to evaluate patient-related predictive factors in connection with genetic polymorphisms
           (Fc gamma and VEGF receptors),

        -  to evaluate ADCC activity via immunohistochemistry in order to analyze the lympho free
           and progression-free survival,

        -  to study circulating of tumor cells as prognostic factor for metastatic colorectal
           cancer, non- resectable at presentation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective is to compare resection rates (R0 or R1) for hepatic metastases</measure>
    <time_frame>at least 4-6 weeks after the end of chemotherapy</time_frame>
    <description>Number of patients (%) with hepatic metastases R0 or R1 resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The objective response rate (CR and PR) after 4 cycles of treatment</measure>
    <time_frame>after 8 weeks</time_frame>
    <description>The objective response rate (CR and PR) will be evaluated by the investigator with RECIST v1.1 criteria after 4 cycles. Patients with symptoms suggestive of disease progression will have a tumoral evaluation when symptoms will occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate (CR) 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients (%) with complete remission (CR) at 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific resection rates R0/R1/R2</measure>
    <time_frame>24 weeks</time_frame>
    <description>Specific resection rates (%) R0/R1/R2 is the rate of patients with a R0, R1 or R2 resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients with Complete pathological response, defined as the absence of tumoral residues after the last chemotherapy cycle. It will be evaluated on liver resection piece, based on total or complete tumor necrosis in all tumor nodules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment</measure>
    <time_frame>Every 2 weeks</time_frame>
    <description>Tolerance of the treatment will be based on toxicities of evaluated products by clinical and biological measurements (NCIC/CTC (CTCAE V4) criteria, except for peripheral neuropathy toxicity (Lévi scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operatory complications</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>Each post operatory complications (Hemorrhage, fistula, insufficiency, heart failure,..) will be graduated using Dindo classification (2004)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>8 months</time_frame>
    <description>Progression-free survival is defined as the time from randomization to progression (RECIST v1.1 criteria) or death. Patients alive without progression will be censored at the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>14 months</time_frame>
    <description>Overall survival is defined as the time from randomization to death any cause or last follow-up news for patients alive (censored data).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every 2 weeks :
irinotecan 180 mg/m² D1
Folinic acid 400 mg/m² D1
5FU 400 mg/m² bolus
5FU 2400 mg/m² infusion over 46 h, D1
And targeted therapy in function of Kras:
For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every 2 weeks :
oxaliplatin 85 mg/m² D1
Folinic acid 400 mg/m² D1
5FU 400 mg/m² bolus
5FU 2400 mg/m² infusion over 46 h, D1
And targeted therapy in function of Kras:
For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks :
oxaliplatin 85 mg/m² D1
irinotecan 150 mg/m² D1
Folinic acid 400 mg/m² D1
5FU 400 mg/m² bolus
5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.
And targeted therapy in function of Kras:
For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days
For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m² over 120 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400mg/m² over 120 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
    <other_name>5-Fluoro uracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180mg/m² over 90 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5mg/kg over 90 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500mg/m² over 90 mn every 2 weeks up to progression or toxicity</description>
    <arm_group_label>Arm A1 : Folfiri + targeted therapy</arm_group_label>
    <arm_group_label>Arm A2 : Folfox 4 + targeted therapy</arm_group_label>
    <arm_group_label>Arm B : Folfirinox + targeted therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal adenocarcinoma,

          -  Primary tumor of the colon or rectum, resectable or resected at least 3 weeks before
             randomization or 4 weeks before the beginning of the study treatment,

          -  Metastatic disease with synchronous or metachronous (&gt; 3 months after diagnosis of the
             primary tumor) hepatic metastasis,

          -  Non-resectable (with respect to curative intent) hepatic metastasis at presentation.
             This criterion must be validated by both a surgeon and a radiologist during the RCP
             (Multidisciplinary cancer case presentation committee) patient's evaluation meeting
             (either technically non-resectable metastases (absolute contraindication): i.e.
             impossibility to resect all metastases in a single operation while preserving at least
             30% of healthy liver tissues and/or impossibility to preserve the portal vein and
             hepatic artery homolateral to the liver or a portal pedicle, or due to oncological
             non-resectability (relative contraindication): presence of &gt; 5 nodules and bilateral
             invasion),

          -  Hepatic metastases, without spread to other sites except in case of ≤ 3 resectable
             pulmonary metastases of diameter &lt; 2 cm, detected by thoracic scanner,

          -  K-Ras status determined before randomization,

          -  Measurable disease according to the RECIST V1.1 criteria,

          -  No prior treatment of the hepatic metastases,

          -  Previous 5FU +/- oxaliplatin-based adjuvant chemotherapy administered after colorectal
             tumor resection is authorized if complete more than 1 year before,

          -  Age ≥ 18 &amp; ≤ 75 years

          -  Performance status : ECOG 0 or 1,

          -  Life expectancy ≥ 3 months,

          -  Hemoglobin ≥ 9 g/dl,

          -  Polynuclear neutrophiles ≥ 1500/mm3,

          -  Platelets ≥ 100 000 mm3,

          -  Creatinemia ≤ 135 µmol/l (1,35 mg/dl)

          -  Total bilirubin ≤ 1.25 times the Upper Limit of Normal (ULN).

          -  Hepatic enzymes ASAT and ALAT &lt; 5 x ULN,

          -  Negative pregnancy test for women of child-bearing age,

          -  Information given to the patient and signed informed consent,

          -  Public Health insurance coverage.

        Exclusion Criteria:

          -  Non metastatic and/or non measurable disease according to the RECIST v1.1 criteria.

          -  Non-resectable primary tumor (e.g.: T4 tumors) or incomplete resection R2.

          -  History of intestinal inflammatory disease.

          -  Specific contraindication to any of the study treatments.

          -  Patient who have previously received anti-EGFr (e.g., cetuximab) or anti-VEGF
             monoclonal antibody treatment (e.g., bevacizumab) or treatment with irinotecan.

          -  History of cancer considered as not cured.

          -  Stroke/CVA or pulmonary embolism within 6 months before inclusion.

          -  Significant concomitant disease such as: coagulopathy, respiratory or cardiac
             congestive insufficiency, non-medically controlled/unstable angina pectoris,
             myocardial infarction within 6 months prior to study entry, arterial hypertension and
             uncontrolled arrhythmia, severe infections.

          -  Clinical neuropathy, grade ≥1.

          -  Patient already included in another therapeutic trial using an experimental molecule.

          -  Pregnant women or women who might become pregnant during the study or lactating women.

          -  Men or women who can procreate and who do not abide with the use of a contraceptive
             means.

          -  Persons kept in detention or incapable of giving consent

          -  Patient unwilling or unable to comply with the medical follow-up required by the trial
             because of geographic social or psychological reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc YCHOU, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Val d'Aurelle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric FRANCOIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne-NICE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent MINEUR, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Ste Catherine-AVIGNON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier BOUCHE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Driffa MOUSSATA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Lyon Sud-PIERRE BENITE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosine GUIMBAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Rangueil-TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger FAROUX, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendée -LA ROCHE SUR YON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karine BOUHIER-LEPORRIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Côte de Nacre-CAEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice GAGNAIRE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon - Hôp. Du Bocage</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves BECOUARN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié-BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François GHIRINGHELLI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre G. F. Leclerc-DIJON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosine GUIMBAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Purpan-TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaël DEPLANQUE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Saint-Joseph-PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien FORESTIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Edouard Herriot-LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascale MARIANI, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis LEGOUX, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans - La Source</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cédric LECAILLE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique de Bordeaux Nord</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Pierre GALAIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse-CAEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe HOUYAU, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Claude Bernard -ALBI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Non-resectable hepatic metastases</keyword>
  <keyword>First-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

